Hyperaluminaemia in critically ill patients: role of antacid therapy and impaired renal function
| Autor: | U. Gladziwa, W. Mück, H.G. Sieberth, T.H. Ittel |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male inorganic chemicals medicine.medical_specialty Magnesium Hydroxide Critical Care medicine.medical_treatment Clinical Biochemistry Renal function chemistry.chemical_element Aluminum Hydroxide complex mixtures Biochemistry Gastroenterology Impaired renal function Antacid therapy Antacid Aluminium Magaldrate Internal medicine medicine Humans Aged Aged 80 and over Critically ill business.industry General Medicine Acute Kidney Injury Middle Aged respiratory system respiratory tract diseases Surgery Intestinal Absorption chemistry Toxicity Kidney Failure Chronic Female Kidney Diseases Antacids business Aluminum medicine.drug |
| Zdroj: | European Journal of Clinical Investigation. 21:96-102 |
| ISSN: | 1365-2362 0014-2972 |
| DOI: | 10.1111/j.1365-2362.1991.tb01365.x |
| Popis: | A significant rise in serum concentrations of aluminium was demonstrated in 23 patients prophylactically treated with the antacid magaldrate, whereas no increase in serum aluminium was observed in another 26 critically ill patients, in whom the use of antacids was avoided. In parallel, urinary excretion rates of aluminium rose to values close to maximum 72 h after antacid therapy had been started. Hyperaluminaemia was most marked in patients with acute renal failure undergoing continuous haemofiltration, but a significant increment in serum aluminium was also noted in patients with impaired renal function in the predialytic state. In the latter group and in patients with normal renal function there was a significant negative correlation between urinary excretion rates of aluminium and creatinine clearance after 48 h of treatment suggesting an enhancement of gastrointestinal absorption of aluminium in the presence of chronic renal failure. Maximum serum concentrations of aluminium did attain critical values in some patients with acute renal failure, but no overt signs of aluminium toxicity were noted. However, in light of both, possible subtle toxicity and enhanced absorption of aluminium in critically ill patients with renal failure, the prophylactic use of antacids in this setting should be reevaluated cautiously. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text